Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 0.41 |
| ▸ | RARG | P13631 | 14/20 | 0.41 |
| ▸ | RARA | P10276 | 12/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27337657 | 0.95 | RARB (0.40) | RARBRARGRARAKCNH2HRH3 | |
| SCHEMBL27338665 | 0.89 | RARB (0.40) | RARBRARGRARAKCNH2HRH3 | |
| SCHEMBL27338351 | 0.80 | RARB (0.40) | RARBRARGRARAKCNH2HRH3 | |
| SCHEMBL27337626 | 0.80 | RARG (0.55) | RARBRARGRARA | |
| SCHEMBL27337627 | 0.79 | RARG (0.49) | RARBRARGRARA | |
| SCHEMBL27337702 | 0.78 | RARG (0.66) | RARBRARGRARA | |
| SCHEMBL27337698 | 0.77 | RARG (0.60) | RARBRARGRARA | |
| SCHEMBL27158932 | 0.77 | PTPN11 (0.44) | KCNH2HRH3PDGFRBPDGFRA | |
| SCHEMBL29976974 | 0.76 | RARB (0.49) | RARBRARGRARAKCNH2HRH3 | |
| SCHEMBL27338618 | 0.75 | RARB (0.39) | RARBRARGRARAKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | RARA, RARG, RXRG | RARB 4/4885RARG 2/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.